查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1487561

风湿病治疗市场（药物类别：改变疾病的抗风湿药、非类固醇抗发炎药、皮质类固醇、尿酸药物等）-全球产业分析、规模、份额、成长、趋势和预测，2024-2034

Rheumatology Therapeutics Market (Drug Class: Disease Modifying Anti-rheumatic Drugs, Nonsteroidal Anti-inflammatory Drugs, Corticosteroids, Uric Acid Drugs, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
出版日期: | 出版商: Transparency Market Research | 英文 205 Pages | 商品交期: 2-10个工作天内

价格

风湿病治疗市场 - 报告范围

TMR 关于全球风湿病治疗市场的报告研究了过去以及当前的成长趋势和机会，以获得 2024 年至 2034 年预测期内市场指标的宝贵见解。年期间，考虑2024年为基准年，2034年为预测年。该报告也提供了2024年至2034年全球风湿病治疗市场的年复合成长率（CAGR%）。

该报告是经过广泛研究后编写的。初级研究涉及大部分研究工作，其中分析师对关键意见领袖、行业领导者和舆论製造者进行了采访。二次研究涉及参考主要参与者的产品文献、年度报告、新闻稿和相关文件，以了解风湿病治疗市场。

市场概况
2023年市场价值 488 亿美元
2034 年市场价值 651 亿美元
复合年增长率 2.6%

该报告深入探讨了全球风湿病治疗市场的竞争格局。全球风湿病治疗市场的主要参与者已经确定，并且每位参与者都根据不同的属性进行了分析。公司概况、财务状况、最新发展和 SWOT 是本报告中介绍的全球风湿病治疗市场参与者的属性。

目录

第一章：前言

第 2 章：假设与研究方法

第 3 章：执行摘要：全球市场

第 4 章：市场概览

  • 介绍
  • 概述
  • 市场动态
  • 2020-2034年全球市场分析与预测

第 5 章：关键见解

  • 管道分析
  • 主要产品/品牌分析
  • 主要併购
  • COVID-19 大流行对该行业的影响

第 6 章：全球市场分析与预测：依药物类别

  • 简介和定义
  • 主要发现/进展
  • 市场价值预测：依药品类别，2020-2034
    • 疾病缓解抗风湿药物 (DMARD)
      • 合成疾病缓解抗风湿药物
      • 生物疾病缓解抗风湿药物
    • 非类固醇类抗发炎药 (NSAID)
    • 皮质类固醇
    • 降尿酸药物
    • 其他的
  • 市场吸引力：按药品类别

第 7 章：全球市场分析与预测：按疾病适应症

  • 简介和定义
  • 主要发现/进展
  • 市场价值预测：依疾病适应症，2020-2034
    • 类风湿关节炎
    • 骨关节炎
    • 痛风
    • 银屑病关节炎
    • 僵直性脊椎炎
    • 其他的
  • 市场吸引力：依疾病适应症分类

第 8 章：全球市场分析与预测：依给药途径

  • 简介和定义
  • 主要发现/进展
  • 市场价值预测：依给药途径，2020-2034年
    • 肠外途径
    • 口头途径
    • 专题
  • 市场吸引力：依给药途径分类

第 9 章：全球市场分析与预测：按配销通路

  • 简介和定义
  • 主要发现/进展
  • 市场价值预测：按配销通路，2020-2034
    • 医院药房
    • 零售药房
    • 网路药房
  • 市场吸引力：按配销通路划分

第 10 章：全球市场分析与预测：按地区

  • 主要发现
  • 市场价值预测：按地区，2020-2034
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 市场吸引力：按地区

第 11 章：北美市场分析与预测

第 12 章：欧洲市场分析与预测

第 13 章：亚太市场分析与预测

第 14 章：拉丁美洲市场分析与预测

第 15 章：中东和非洲市场分析与预测

第16章：竞争格局

  • 市场参与者 - 竞争矩阵（依公司层级和规模）
  • 市占率分析：依公司分类（2023）
  • 公司简介
    • F. Hoffmann-La Roche Ltd.
    • AbbVie, Inc.
    • Pfizer, Inc.
    • Takeda Pharmaceutical Company Limited
    • Amgen, Inc.
    • Genentech, Inc.
    • Novartis AG
    • Johnson & Johnson Innovative Medicine
    • Sanofi
    • Merck & Co., Inc.
Product Code: TMRGL1494

Rheumatology Therapeutics Market - Scope of Report

TMR's report on the global rheumatology therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global rheumatology therapeutics market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global rheumatology therapeutics market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the rheumatology therapeutics market.

Market Snapshot
Market Value in 2023US$ 48.8 Bn
Market Value in 2034US$ 65.1 Bn
CAGR2.6%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global rheumatology therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global rheumatology therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global rheumatology therapeutics market.

The report delves into the competitive landscape of the global rheumatology therapeutics market. Key players operating in the global rheumatology therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global rheumatology therapeutics market profiled in this report.

Key Questions Answered in Global rheumatology therapeutics Market Report:

  • What is the sales/revenue generated by rheumatology therapeutics across all regions during the forecast period?
  • What are the opportunities in the global rheumatology therapeutics market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Rheumatology Therapeutics Market - Research Objectives and Research Approach

The comprehensive report on the global rheumatology therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global rheumatology therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global rheumatology therapeutics market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Rheumatology Therapeutics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Rheumatology Therapeutics Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Rheumatology Therapeutics Market Analysis and Forecast, by Drug Class

  • 6.1. Introduction and Definitions
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Drug Class, 2020-2034
    • 6.3.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
      • 6.3.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
      • 6.3.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
    • 6.3.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    • 6.3.3. Corticosteroids
    • 6.3.4. Uric Acid Drugs
    • 6.3.5. Others
  • 6.4. Market Attractiveness, by Drug Class

7. Global Rheumatology Therapeutics Market Analysis and Forecast, by Disease Indication

  • 7.1. Introduction and Definitions
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Disease Indication, 2020-2034
    • 7.3.1. Rheumatoid Arthritis
    • 7.3.2. Osteoarthritis
    • 7.3.3. Gout
    • 7.3.4. Psoriatic Arthritis
    • 7.3.5. Ankylosing Spondylitis
    • 7.3.6. Others
  • 7.4. Market Attractiveness, by Disease Indication

8. Global Rheumatology Therapeutics Market Analysis and Forecast, by Route of Administration

  • 8.1. Introduction and Definitions
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Route of Administration, 2020-2034
    • 8.3.1. Parenteral Route
    • 8.3.2. Oral Route
    • 8.3.3. Topical
  • 8.4. Market Attractiveness, by Route of Administration

9. Global Rheumatology Therapeutics Market Analysis and Forecast, by Distribution Channel

  • 9.1. Introduction and Definitions
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by Distribution Channel, 2020-2034
    • 9.3.1. Hospital Pharmacy
    • 9.3.2. Retail Pharmacy
    • 9.3.3. Online Pharmacy
  • 9.4. Market Attractiveness, by Distribution Channel

10. Global Rheumatology Therapeutics Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast, by Region, 2020-2034
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness, by Region

11. North America Rheumatology Therapeutics Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Drug Class, 2020-2034
    • 11.2.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
      • 11.2.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
      • 11.2.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
    • 11.2.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    • 11.2.3. Corticosteroids
    • 11.2.4. Uric Acid Drugs
    • 11.2.5. Others
  • 11.3. Market Attractiveness, by Drug Class
  • 11.4. Market Value Forecast, by Disease Indication, 2020-2034
    • 11.4.1. Rheumatoid Arthritis
    • 11.4.2. Osteoarthritis
    • 11.4.3. Gout
    • 11.4.4. Psoriatic Arthritis
    • 11.4.5. Ankylosing Spondylitis
    • 11.4.6. Others
  • 11.5. Market Attractiveness, by Disease Indication
  • 11.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 11.6.1. Parenteral Route
    • 11.6.2. Oral Route
    • 11.6.3. Topical
  • 11.7. Market Attractiveness, by Route of Administration
  • 11.8. Market Value Forecast, by Distribution Channel, 2020-2034
    • 11.8.1. Hospital Pharmacy
    • 11.8.2. Retail Pharmacy
    • 11.8.3. Online Pharmacy
  • 11.9. Market Attractiveness, by Distribution Channel
  • 11.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 11.10.1. U.S.
    • 11.10.2. Canada
  • 11.11. Market Attractiveness Analysis
    • 11.11.1. By Drug Class
    • 11.11.2. By Disease Indication
    • 11.11.3. By Route of Administration
    • 11.11.4. By Distribution Channel
    • 11.11.5. By Country

12. Europe Rheumatology Therapeutics Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Drug Class, 2020-2034
    • 12.2.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
      • 12.2.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
      • 12.2.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
    • 12.2.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    • 12.2.3. Corticosteroids
    • 12.2.4. Uric Acid Drugs
    • 12.2.5. Others
  • 12.3. Market Attractiveness, by Drug Class
  • 12.4. Market Value Forecast, by Disease Indication, 2020-2034
    • 12.4.1. Rheumatoid Arthritis
    • 12.4.2. Osteoarthritis
    • 12.4.3. Gout
    • 12.4.4. Psoriatic Arthritis
    • 12.4.5. Ankylosing Spondylitis
    • 12.4.6. Others
  • 12.5. Market Attractiveness, by Disease Indication
  • 12.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 12.6.1. Parenteral Route
    • 12.6.2. Oral Route
    • 12.6.3. Topical
  • 12.7. Market Attractiveness, by Route of Administration
  • 12.8. Market Value Forecast, by Distribution Channel, 2020-2034
    • 12.8.1. Hospital Pharmacy
    • 12.8.2. Retail Pharmacy
    • 12.8.3. Online Pharmacy
  • 12.9. Market Attractiveness, by Distribution Channel
  • 12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.10.1. Germany
    • 12.10.2. U.K.
    • 12.10.3. France
    • 12.10.4. Italy
    • 12.10.5. Spain
    • 12.10.6. Rest of Europe
  • 12.11. Market Attractiveness Analysis
    • 12.11.1. By Drug Class
    • 12.11.2. By Disease Indication
    • 12.11.3. By Route of Administration
    • 12.11.4. By Distribution Channel
    • 12.11.5. By Country/Sub-region

13. Asia Pacific Rheumatology Therapeutics Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Drug Class, 2020-2034
    • 13.2.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
      • 13.2.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
      • 13.2.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
    • 13.2.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    • 13.2.3. Corticosteroids
    • 13.2.4. Uric Acid Drugs
    • 13.2.5. Others
  • 13.3. Market Attractiveness, by Drug Class
  • 13.4. Market Value Forecast, by Disease Indication, 2020-2034
    • 13.4.1. Rheumatoid Arthritis
    • 13.4.2. Osteoarthritis
    • 13.4.3. Gout
    • 13.4.4. Psoriatic Arthritis
    • 13.4.5. Ankylosing Spondylitis
    • 13.4.6. Others
  • 13.5. Market Attractiveness, by Disease Indication
  • 13.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 13.6.1. Parenteral Route
    • 13.6.2. Oral Route
    • 13.6.3. Topical
  • 13.7. Market Attractiveness, by Route of Administration
  • 13.8. Market Value Forecast, by Distribution Channel, 2020-2034
    • 13.8.1. Hospital Pharmacy
    • 13.8.2. Retail Pharmacy
    • 13.8.3. Online Pharmacy
  • 13.9. Market Attractiveness, by Distribution Channel
  • 13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.10.1. China
    • 13.10.2. Japan
    • 13.10.3. India
    • 13.10.4. Australia & New Zealand
    • 13.10.5. Rest of Asia Pacific
  • 13.11. Market Attractiveness Analysis
    • 13.11.1. By Drug Class
    • 13.11.2. By Disease Indication
    • 13.11.3. By Route of Administration
    • 13.11.4. By Distribution Channel
    • 13.11.5. By Country/Sub-region

14. Latin America Rheumatology Therapeutics Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Drug Class, 2020-2034
    • 14.2.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
      • 14.2.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
      • 14.2.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
    • 14.2.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    • 14.2.3. Corticosteroids
    • 14.2.4. Uric Acid Drugs
    • 14.2.5. Others
  • 14.3. Market Attractiveness, by Drug Class
  • 14.4. Market Value Forecast, by Disease Indication, 2020-2034
    • 14.4.1. Rheumatoid Arthritis
    • 14.4.2. Osteoarthritis
    • 14.4.3. Gout
    • 14.4.4. Psoriatic Arthritis
    • 14.4.5. Ankylosing Spondylitis
    • 14.4.6. Others
  • 14.5. Market Attractiveness, by Disease Indication
  • 14.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 14.6.1. Parenteral Route
    • 14.6.2. Oral Route
    • 14.6.3. Topical
  • 14.7. Market Attractiveness, by Route of Administration
  • 14.8. Market Value Forecast, by Distribution Channel, 2020-2034
    • 14.8.1. Hospital Pharmacy
    • 14.8.2. Retail Pharmacy
    • 14.8.3. Online Pharmacy
  • 14.9. Market Attractiveness, by Distribution Channel
  • 14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 14.10.1. Brazil
    • 14.10.2. Mexico
    • 14.10.3. Rest of Latin America
  • 14.11. Market Attractiveness Analysis
    • 14.11.1. By Drug Class
    • 14.11.2. By Disease Indication
    • 14.11.3. By Route of Administration
    • 14.11.4. By Distribution Channel
    • 14.11.5. By Country/Sub-region

15. Middle East & Africa Rheumatology Therapeutics Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Drug Class, 2020-2034
    • 15.2.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
      • 15.2.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
      • 15.2.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
    • 15.2.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    • 15.2.3. Corticosteroids
    • 15.2.4. Uric Acid Drugs
    • 15.2.5. Others
  • 15.3. Market Attractiveness, by Drug Class
  • 15.4. Market Value Forecast, by Disease Indication, 2020-2034
    • 15.4.1. Rheumatoid Arthritis
    • 15.4.2. Osteoarthritis
    • 15.4.3. Gout
    • 15.4.4. Psoriatic Arthritis
    • 15.4.5. Ankylosing Spondylitis
    • 15.4.6. Others
  • 15.5. Market Attractiveness, by Disease Indication
  • 15.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 15.6.1. Parenteral Route
    • 15.6.2. Oral Route
    • 15.6.3. Topical
  • 15.7. Market Attractiveness, by Route of Administration
  • 15.8. Market Value Forecast, by Distribution Channel, 2020-2034
    • 15.8.1. Hospital Pharmacy
    • 15.8.2. Retail Pharmacy
    • 15.8.3. Online Pharmacy
  • 15.9. Market Attractiveness, by Distribution Channel
  • 15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 15.10.1. GCC Countries
    • 15.10.2. South Africa
    • 15.10.3. Rest of Middle East & Africa
  • 15.11. Market Attractiveness Analysis
    • 15.11.1. By Drug Class
    • 15.11.2. By Disease Indication
    • 15.11.3. By Route of Administration
    • 15.11.4. By Distribution Channel
    • 15.11.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 16.2. Market Share Analysis, by Company (2023)
  • 16.3. Company Profiles
    • 16.3.1. F. Hoffmann-La Roche Ltd.
      • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.1.2. Product Portfolio
      • 16.3.1.3. Financial Overview
      • 16.3.1.4. SWOT Analysis
      • 16.3.1.5. Strategic Overview
    • 16.3.2. AbbVie, Inc.
      • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.2.2. Product Portfolio
      • 16.3.2.3. Financial Overview
      • 16.3.2.4. SWOT Analysis
      • 16.3.2.5. Strategic Overview
    • 16.3.3. Pfizer, Inc.
      • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.3.2. Product Portfolio
      • 16.3.3.3. Financial Overview
      • 16.3.3.4. SWOT Analysis
      • 16.3.3.5. Strategic Overview
    • 16.3.4. Takeda Pharmaceutical Company Limited
      • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.4.2. Product Portfolio
      • 16.3.4.3. Financial Overview
      • 16.3.4.4. SWOT Analysis
      • 16.3.4.5. Strategic Overview
    • 16.3.5. Amgen, Inc.
      • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.5.2. Product Portfolio
      • 16.3.5.3. Financial Overview
      • 16.3.5.4. SWOT Analysis
      • 16.3.5.5. Strategic Overview
    • 16.3.6. Genentech, Inc.
      • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.6.2. Product Portfolio
      • 16.3.6.3. Financial Overview
      • 16.3.6.4. SWOT Analysis
      • 16.3.6.5. Strategic Overview
    • 16.3.7. Novartis AG
      • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.7.2. Product Portfolio
      • 16.3.7.3. Financial Overview
      • 16.3.7.4. SWOT Analysis
      • 16.3.7.5. Strategic Overview
    • 16.3.8. Johnson & Johnson Innovative Medicine
      • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.8.2. Product Portfolio
      • 16.3.8.3. Financial Overview
      • 16.3.8.4. SWOT Analysis
      • 16.3.8.5. Strategic Overview
    • 16.3.9. Sanofi
      • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.9.2. Product Portfolio
      • 16.3.9.3. Financial Overview
      • 16.3.9.4. SWOT Analysis
      • 16.3.9.5. Strategic Overview
    • 16.3.10. Merck & Co., Inc.
      • 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.10.2. Product Portfolio
      • 16.3.10.3. Financial Overview
      • 16.3.10.4. SWOT Analysis
      • 16.3.10.5. Strategic Overview

List of Tables

  • Table 01: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034
  • Table 02: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2020-2034
  • Table 03: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
  • Table 04: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034
  • Table 05: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Region, 2020-2034
  • Table 06: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Country, 2020-2034
  • Table 07: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034
  • Table 08: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2020-2034
  • Table 09: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034
  • Table 10: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
  • Table 11: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 12: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034
  • Table 13: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2020-2034
  • Table 14: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034
  • Table 15: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
  • Table 16: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 17: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034
  • Table 18: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2020-2034
  • Table 19: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034
  • Table 20: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
  • Table 21: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 22: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034
  • Table 23: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2020-2034
  • Table 24: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034
  • Table 25: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
  • Table 26: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 27: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034
  • Table 28: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2020-2034
  • Table 29: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034
  • Table 30: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034

List of Figures

  • Figure 01: Global Rheumatology Therapeutics Market Size (US$ Mn), by Region, 2023 and 2034
  • Figure 02: Global Rheumatology Therapeutics Market Revenue (US$ Mn), by Drug Class, 2023
  • Figure 03: Global Rheumatology Therapeutics Market Value Share, by Drug Class, 2023
  • Figure 04: Global Rheumatology Therapeutics Market Revenue (US$ Mn), by Disease Indication, 2023
  • Figure 05: Global Rheumatology Therapeutics Market Value Share, by Disease Indication, 2023
  • Figure 06: Global Rheumatology Therapeutics Market Revenue (US$ Mn), by Route of Administration, 2023
  • Figure 07: Global Rheumatology Therapeutics Market Value Share, by Route of Administration, 2023
  • Figure 08: Global Rheumatology Therapeutics Market Revenue (US$ Mn), by Distribution Channel, 2023
  • Figure 09: Global Rheumatology Therapeutics Market Value Share, by Distribution Channel, 2023
  • Figure 10: Global Rheumatology Therapeutics Market Value Share, by Region, 2023
  • Figure 11: Global Rheumatology Therapeutics Market Value (US$ Mn) Forecast, 2020-2034
  • Figure 12: Global Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 13: Global Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2024-2034
  • Figure 14: Global Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2023 and 2034
  • Figure 15: Global Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2024-2034
  • Figure 16: Global Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 17: Global Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 18: Global Rheumatology Therapeutics Market Revenue (US$ Mn), by Distribution Channel, 2023
  • Figure 19: Global Rheumatology Therapeutics Market Value Share, by Distribution Channel, 2023
  • Figure 20: Global Rheumatology Therapeutics Market Value Share Analysis, by Region, 2023 and 2034
  • Figure 21: Global Rheumatology Therapeutics Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 22: North America Rheumatology Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 23: North America Rheumatology Therapeutics Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 24: North America Rheumatology Therapeutics Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 25: North America Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 26: North America Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2023 and 2034
  • Figure 27: North America Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 28: North America Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 29: North America Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2024-2034
  • Figure 30: North America Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2024-2034
  • Figure 31: North America Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 32: North America Rheumatology Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 33: Europe Rheumatology Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 34: Europe Rheumatology Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 35: Europe Rheumatology Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 36: Europe Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 37: Europe Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2023 and 2034
  • Figure 38: Europe Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 39: Europe Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 40: Europe Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2024-2034
  • Figure 41: Europe Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2024-2034
  • Figure 42: Europe Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 43: Europe Rheumatology Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 44: Asia Pacific Rheumatology Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 45: Asia Pacific Rheumatology Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 46: Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 47: Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 48: Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2023 and 2034
  • Figure 49: Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 50: Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 51: Asia Pacific Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2024-2034
  • Figure 52: Asia Pacific Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2024-2034
  • Figure 53: Asia Pacific Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 54: Asia Pacific Rheumatology Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023-2034
  • Figure 55: Latin America Rheumatology Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 56: Latin America Rheumatology Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 57: Latin America Rheumatology Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 58: Latin America Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 59: Latin America Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2023 and 2034
  • Figure 60: Latin America Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 61: Latin America Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 62: Latin America Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2024-2034
  • Figure 63: Latin America Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2024-2034
  • Figure 64: Latin America Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 65: Latin America Rheumatology Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 66: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 67: Middle East & Africa Rheumatology Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 68: Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 69: Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 70: Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2023 and 2034
  • Figure 71: Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 72: Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 73: Middle East & Africa Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2024-2034
  • Figure 74: Middle East & Africa Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2024-2034
  • Figure 75: Middle East & Africa Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 76: Middle East & Africa Rheumatology Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2024-2034